{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field f4a488ab-3f95-4ec0-bdb7-bc3cb48a26f0 --><h2>Update</h2><!-- end field f4a488ab-3f95-4ec0-bdb7-bc3cb48a26f0 -->","summary":null,"htmlStringContent":"<!-- begin item 4ed9da32-7143-4341-b8a0-cc062dfdc9f3 --><!-- end item 4ed9da32-7143-4341-b8a0-cc062dfdc9f3 -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"69338c48-0d43-5ae0-9591-5ef289880366","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"7cf808eb-a383-5931-86d8-7cbad460495f","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field a7a65a47-b076-4a94-a9f8-c898ce8288b5 --><h3>New evidence</h3><!-- end field a7a65a47-b076-4a94-a9f8-c898ce8288b5 -->","summary":null,"htmlStringContent":"<!-- begin item d62eac9c-10d7-4e53-9c36-5720128626de --><!-- begin field eec3ccad-43d6-4481-a9a5-bbe1868c3bbc --><h3>Evidence-based guidelines</h3><!-- end field eec3ccad-43d6-4481-a9a5-bbe1868c3bbc --><!-- begin field 3f44d5cd-4cf4-47eb-b0a0-6d2735a1a589 --><ul><li>FitzGerald, J.D., Dalbeth, N., Mikuls, T. et al. (2020) <em>2020 American College of Rheumatology guideline for the management of gout</em>. <a href=\"https://onlinelibrary.wiley.com/\" data-hyperlink-id=\"a6cd971b-4a3e-48f8-98f7-abbc0097bc4f\">www.onlinelibrary.wiley.com</a> [<a href=\"https://onlinelibrary.wiley.com/doi/10.1002/art.41247\" data-hyperlink-id=\"8bb2fd0b-8fd2-4dc6-920e-abbc0097bddc\">Free Full-text</a>]</li></ul><!-- end field 3f44d5cd-4cf4-47eb-b0a0-6d2735a1a589 --><!-- begin field 7a14c25a-075a-49bb-a781-d4919cf90209 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 7a14c25a-075a-49bb-a781-d4919cf90209 --><!-- begin field 1d0c2ef5-590d-4250-bc56-65a9d1bb1081 --><p>No new technology appraisals published since 1 October 2017.</p><!-- end field 1d0c2ef5-590d-4250-bc56-65a9d1bb1081 --><!-- begin field 1dae9245-5023-491e-936d-8570bb87b64a --><h3>Economic appraisals</h3><!-- end field 1dae9245-5023-491e-936d-8570bb87b64a --><!-- begin field f1bf00dd-15f7-4ccd-9b08-564ae1b4fec3 --><p>No new economic appraisals relevant to England since 1 October 2017.</p><!-- end field f1bf00dd-15f7-4ccd-9b08-564ae1b4fec3 --><!-- begin field 8262ddd9-5617-4fcf-a65d-a909d3983aca --><h3>Systematic reviews and meta-analyses</h3><!-- end field 8262ddd9-5617-4fcf-a65d-a909d3983aca --><!-- begin field a543c7fb-b1c3-44d8-98cc-ee82e02c9158 --><ul><li>Yang, N., Yu, Y., Zhang, A., et al. (2019) <em>Reporting, presentation and wording of recommendations in clinical practice guideline for gout: a systematic analysis. </em>BMJ Journals. <a href=\"https://bmjopen.bmj.com/\" data-hyperlink-id=\"cee035f7-6d32-4806-9939-a9fc00b72438\">www.bmjopen.bmj.com</a> [<a href=\"https://bmjopen.bmj.com/content/9/1/e024315\" data-hyperlink-id=\"6c0b85b2-fb26-4270-9e1a-a9fc00b7244c\">Free Full-text</a>]</li><li>Safiri, S., Kolahi, A.A., Cross, M., et al. (2020) <em>Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: a systematic analysis of the global burden of disease study 2017.</em> Arthritis and Rheumatology. <a href=\"https://onlinelibrary.wiley.com/\" data-hyperlink-id=\"4e9b7295-6be3-4ab3-916c-ac3300e76895\">www.onlinelibrary.wiley.com</a> [<a href=\"https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41404\" data-hyperlink-id=\"76367064-6101-4a63-be54-ac3300e76998\">Abstract</a>]</li></ul><!-- end field a543c7fb-b1c3-44d8-98cc-ee82e02c9158 --><!-- begin field 9712dd84-533a-4931-9d65-2725e2c50389 --><h3>Primary evidence</h3><!-- end field 9712dd84-533a-4931-9d65-2725e2c50389 --><!-- begin field f11415e8-ff31-4a75-abb3-356a0fa90a4f --><p>No new randomized controlled trials published in the major journals since 1 October 2017.</p><!-- end field f11415e8-ff31-4a75-abb3-356a0fa90a4f --><!-- end item d62eac9c-10d7-4e53-9c36-5720128626de -->","subChapters":[]},{"id":"7b01d8d9-9afc-564d-9910-6dba3c155f82","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field de699575-af74-4afa-88a0-49d44a527fd8 --><h3>New policies</h3><!-- end field de699575-af74-4afa-88a0-49d44a527fd8 -->","summary":null,"htmlStringContent":"<!-- begin item 6b3f3e55-3052-47ce-a739-a6d0e53ea7e9 --><!-- begin field 8eec7a24-50ab-4345-905d-3fdf8e55938a --><p>No new national policies or guidelines since 1 October 2017.</p><!-- end field 8eec7a24-50ab-4345-905d-3fdf8e55938a --><!-- end item 6b3f3e55-3052-47ce-a739-a6d0e53ea7e9 -->","subChapters":[]},{"id":"1d24802a-15ae-5d46-b657-3d27dc0e1925","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 36a39f4c-a682-48c4-bd57-e60f272d6b7f --><h3>New safety alerts</h3><!-- end field 36a39f4c-a682-48c4-bd57-e60f272d6b7f -->","summary":null,"htmlStringContent":"<!-- begin item b2c7597b-4960-4222-a922-f242086c5176 --><!-- begin field c1a16d23-d8f5-429d-91e7-1a6838e39b8b --><p>No new safety alerts since 1 October 2017.</p><!-- end field c1a16d23-d8f5-429d-91e7-1a6838e39b8b --><!-- end item b2c7597b-4960-4222-a922-f242086c5176 -->","subChapters":[]},{"id":"3e7d9d92-dc07-54a3-9211-8998b7e0bb10","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 861b53eb-1ed8-4396-9f29-a83c817b648b --><h3>Changes in product availability</h3><!-- end field 861b53eb-1ed8-4396-9f29-a83c817b648b -->","summary":null,"htmlStringContent":"<!-- begin item d616366d-ccdb-49ac-bec4-6c1cefbc83f3 --><!-- begin field 16f7c2e9-55a6-4bf1-b215-606fcc26d894 --><ul><li>European CHMP recommends approval of Duzallo (lesinurad and allopurinol) for treatment of hyperuricaemia in gout. See <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004412/WC500251152.pdf\" data-hyperlink-id=\"4f693444-d5a7-4754-8266-a91500b32f8f\">here</a> for more information. </li></ul><!-- end field 16f7c2e9-55a6-4bf1-b215-606fcc26d894 --><!-- end item d616366d-ccdb-49ac-bec4-6c1cefbc83f3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}